Roth Capital Downgrades Tonix Pharma (TNXP) to Neutral Citing PTSD Setback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P dip, trading choppy as tech stocks fall
- Brent hits lowest since before start of Iran war as more tankers exit Hormuz, easing supply
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Brookline Capital Markets Downgrades Tonix Pharma (TNXP) to Hold
July 27, 2018 10:04 AM EDTBrookline Capital Markets downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Hold.
For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.
Shares of Tonix Pharma closed at $3.95 yesterday.
... MoreUPDATE: B.Riley/FBR Downgrades Tonix Pharma (TNXP) to Neutral
July 27, 2018 10:04 AM EDT(Updated - July 30, 2018 9:04 AM EDT)
(updated to add analyst comment)
B.Riley/FBR downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Neutral with a price target of $1.25 (from $8.00).
Analyst David Buck comments "We downgrade our rating for Tonix Pharmaceuticals Holding... More
Tonix Pharma (TNXP) Halted on LUDP
July 27, 2018 9:59 AM EDTTonix Pharma (NASDAQ: TNXP) Halted on LUDP
... More